Drug Type Fc fusion protein, Biosimilar |
Synonyms Aflibercept Biosimilar (Alteogen, Inc.), Eylea Biosimilar, 阿柏西普生物类似药(Alteogen, Inc.) + [3] |
Target |
Action inhibitors |
Mechanism PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (17 Sep 2025), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetic macular oedema | European Union | 17 Sep 2025 | |
Diabetic macular oedema | Iceland | 17 Sep 2025 | |
Diabetic macular oedema | Liechtenstein | 17 Sep 2025 | |
Diabetic macular oedema | Norway | 17 Sep 2025 | |
Myopic choroidal neovascularization | European Union | 17 Sep 2025 | |
Myopic choroidal neovascularization | Iceland | 17 Sep 2025 | |
Myopic choroidal neovascularization | Liechtenstein | 17 Sep 2025 | |
Myopic choroidal neovascularization | Norway | 17 Sep 2025 | |
Retinal vein occlusion-related macular edema | European Union | 17 Sep 2025 | |
Retinal vein occlusion-related macular edema | Iceland | 17 Sep 2025 | |
Retinal vein occlusion-related macular edema | Liechtenstein | 17 Sep 2025 | |
Retinal vein occlusion-related macular edema | Norway | 17 Sep 2025 | |
Wet age-related macular degeneration | European Union | 17 Sep 2025 | |
Wet age-related macular degeneration | Iceland | 17 Sep 2025 | |
Wet age-related macular degeneration | Liechtenstein | 17 Sep 2025 | |
Wet age-related macular degeneration | Norway | 17 Sep 2025 |